Trials / Conditions / Molecular Mechanisms of Pharmacological Action

Molecular Mechanisms of Pharmacological Action

25 registered clinical trials studyying Molecular Mechanisms of Pharmacological Action — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB NCT06535568	Fondazione Ricerca e Innovazione Cardiovascolare ETS	N/A
Recruiting	A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU) NCT07210463	Merz Aesthetics GmbH	Phase 3
Recruiting	A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States NCT07122193	Merz North America, Inc.	Phase 3
Recruiting	Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Trea NCT06511908	National Institute of Mental Health (NIMH)	Phase 2
Recruiting	Natural History of Depression, Bipolar Disorder and Suicide Risk NCT06462196	National Institute of Mental Health (NIMH)	—
Recruiting	Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINST NCT05465031	Silesian Centre for Heart Diseases	Phase 4
Unknown	Propranolol on Post Stroke Immune Status and Infection NCT05375240	Tianjin Medical University General Hospital	Phase 2
Recruiting	Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors a NCT04572451	Yana Najjar	Phase 1
Completed	Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder NCT05321602	Luye Pharma Group Ltd.	Phase 1
Completed	Relative Bioavailability of LY03010 Compared to Listed Drug NCT04922593	Luye Pharma Group Ltd.	Phase 1
Completed	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader NCT05657860	Maimonides Medical Center	Phase 4
Unknown	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian NCT04556071	Xiaoxiang Chen	Phase 2
Terminated	Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM NCT04489420	Celularity Incorporated	Phase 1
Completed	TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC NCT04518852	Sichuan Cancer Hospital and Research Institute	Phase 2
Recruiting	Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients NCT04289142	Sunnybrook Health Sciences Centre	Phase 4
Unknown	Citalopram and Self Emotional Processing NCT04169230	University of Oxford	N/A
Unknown	Pharmacometabolomics of Andrographis Paniculata And Metformin In Healthy Volunteers Under Fasting Condition NCT04161404	University of Malaya	Phase 1
Unknown	The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer NCT03889626	Fudan University	Phase 3
Completed	Antidiabetic Drugs for Steatotic Liver Disease NCT03646292	Yonsei University	Phase 4
Completed	Using Non-invasive Brain Stimulation (tDCS) With Varenicline for Treating Tobacco Dependence NCT03841292	Centre for Addiction and Mental Health	N/A
Completed	Effects of Seven Day Prucalopride Administration in Healthy Volunteers NCT03572790	University of Oxford	N/A
Unknown	Acceptable Hemodynamic Changes in Dexmedetomidine for Single Intravenous Bolus Injection NCT03655847	Second Affiliated Hospital of Wenzhou Medical University	Phase 4
Completed	Avelumab in Refractory Testicular Germ Cell Cancer. NCT03403777	National Cancer Institute, Slovakia	Phase 2
Completed	A Study to Investigate the Mass Balance of BTD-001 NCT03107013	Balance Therapeutics	Phase 1
Completed	Effects of Acute Prucalopride Administration in Healthy Volunteers NCT03863366	University of Oxford	N/A